Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 11, 2026
TickeronGET DAILY SIGNALS
Marsh & McLennan (MRSH) Earnings Preview: Steady Growth Expected in Q3 2026

Marsh & McLennan (MRSH) Earnings Preview: Steady Growth Expected in Q3 2026

Key Takeaways

  • Marsh & McLennan Companies (MRSH) — now operating under the "Marsh" brand — is scheduled to report third-quarter 2026 results before the market opens on Thursday, October 15, 2026.
  • Wall Street consensus calls for adjusted earnings per share (EPS) of roughly $1.96, an increase of about 6% from $1.85 in the year-ago quarter.
  • Analysts expect revenue near $6.6 billion, up approximately 4.5% from about $6.35 billion a year earlier.
  • Marsh has beaten consensus EPS estimates in each of its last four quarters, most recently posting adjusted EPS of $2.96 in the second quarter of 2026.
  • Investors will focus on underlying organic growth, insurance pricing trends, and progress on the company's "Thrive" cost-efficiency program.

Why This Report Matters

Marsh & McLennan Companies stands as a global leader in risk, insurance, reinsurance, and consulting across 130 countries. Its quarterly results offer a useful window into the commercial insurance cycle and corporate demand for advisory work. The company approaches this release with some momentum behind it: adjusted EPS climbed 8% in the first quarter of 2026, and second-quarter figures again came in ahead of expectations. The third-quarter update will show whether that pace can hold as insurance rate increases ease from earlier highs. For investors, it also provides an update on the three-year "Thrive" initiative aimed at boosting efficiency and margins.

What the Numbers Are Expected to Show

For the third quarter ended September 30, 2026, the consensus points to adjusted EPS of about $1.96 versus $1.85 a year earlier, with individual forecasts mostly falling between $1.92 and $2.00. Revenue is modeled around $6.6 billion, reflecting roughly 4.5% year-over-year growth.

Those headline numbers only tell part of the story. Marsh typically releases both GAAP results and adjusted figures that exclude items like restructuring costs and amortization of acquired intangibles. Investors pay close attention to organic revenue growth, which removes the impact of acquisitions and currency moves to highlight core business performance.

Two main segments drive the results: Risk & Insurance Services and Consulting. In the first quarter of 2026, Risk & Insurance Services revenue rose 6% while Consulting advanced 11%, supported by demand for actuarial, health, wealth, and management consulting services. Management has emphasized "underlying revenue growth" as its key metric, and the market will want to see that figure remain in the mid-single-digit range.

Marsh’s recent track record supports some optimism. The company has topped consensus EPS estimates in each of the past four quarters, with an average surprise of about 3% to 4%. Its latest report on July 21, 2026, delivered adjusted EPS of $2.96, ahead of the roughly $2.88 to $2.90 expected.

I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.

Market Sentiment Heading Into the Print

Investor sentiment ahead of the third-quarter report appears mixed. Shares have lagged this year amid concerns that cooling commercial insurance pricing and a softer economic backdrop could slow growth. Marsh is not the only one facing these headwinds; the broader insurance-brokerage group has also faced pressure in 2026.

History shows that beating estimates does not always translate into a positive stock reaction. After strong third-quarter 2025 results, shares dropped sharply in pre-market trading as investors focused on declining insurance rates and broader economic uncertainty. This pattern highlights a potential risk: even an earnings beat could be overshadowed by cautious commentary on pricing or the demand outlook. With shares trading well below their 52-week high, investors will look to see whether results and guidance can shift the narrative toward more durable growth.

What to Watch Going Forward

Beyond the October 15 release, several themes will influence how investors assess Marsh for the rest of 2026 and into 2027.

First is the path of insurance pricing. As rate increases moderate across many commercial lines, the company will need to show that volume growth, client retention, and cross-selling can keep revenue moving. Commentary on property, casualty, and specialty lines will draw particular attention.

Second, the "Thrive" program remains a key focus. Management has targeted meaningful cost savings over three years, and investors will seek evidence that efficiency gains are flowing through to adjusted operating margin expansion without cutting back on growth investments.

Third, mergers and acquisitions continue to serve as a growth tool. Recent and planned deals, including the McGriff insurance-services acquisition and the AltamarCAM expansion into private asset management, will be watched for integration progress and their contribution to results.

Finally, capital allocation remains relevant. Strong free cash flow has backed dividend increases and share buybacks, so any update on the pace of repurchases or deleveraging will be closely examined. For the full year 2026, analysts currently model adjusted EPS of roughly $10.44 on revenue near $28.6 billion, expectations that depend on a solid finish to the year.

Using AI Tools in My Research

In my regular analysis of earnings setups like this one, I often rely on Tickeron’s AI Screener to quickly filter for sector trends, comparable names, and technical signals. It helps surface context around organic growth patterns and valuation without spending hours on manual screens, which keeps my focus on the key drivers for Marsh ahead of the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRSH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MRSH's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for MRSH moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In 17 of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at 52%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for MRSH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 25 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.

MRSH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 57 cases where MRSH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on MRSH as a result. In 48 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

MRSH moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MRSH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.

Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSH advanced for three days, in 164 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.

The Aroon Indicator entered an Uptrend today. In 91 of 263 cases where MRSH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MRSH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.438) is normal, around the industry mean (2.794). P/E Ratio (24.948) is within average values for comparable stocks, (19.877). Projected Growth (PEG Ratio) (1.486) is also within normal values, averaging (8.322). Dividend Yield (0.019) settles around the average of (0.042) among similar stocks. P/S Ratio (3.089) is also within normal values, averaging (3.106).

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 16B. The market cap for tickers in the group ranges from 3.03K to 97.74B. MRSH holds the highest valuation in this group at 97.74B. The lowest valued company is CUII at 3.03K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was -9%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 17%. CRVL experienced the highest price growth at 3%, while ZBAO experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was -73%. For the same stocks of the Industry, the average monthly volume growth was 7% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 74
Price Growth Rating: 51
SMR Rating: 70
Profit Risk Rating: 84
Seasonality Score: 8 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry InsuranceBrokersServices

Industry
N/A
Address
1166 Avenue of the Americas
Phone
+1 212 345-5000
Employees
95000
Web
https://www.corporate.marsh.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.